EXPRESSİON OF EPSTEIN–BARR VIRUS–ENCODED SMALL RNA (BY THE EBER-1 GENE) IN LIVER SPECIMENS FROM TRANSPLANT RECIPIENTS WITH POST-TRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE

PARMJEET S. RANDHAWA, M.D., RONALD JAFFE, M.D., ANTHONY J. DEMETRIS, M.D., MICHAEL NALESNIK, M.D., THOMAS E. STARZL, M.D., PH.D., YUAN YUAN CHEN, B.S., AND LAWRENCE M. WEISS, M.D.

Abstract Background. Epstein–Barr virus (EBV)–associated post-transplantation lymphoproliferative disease (PTLD) develops in 1 to 10 percent of transplant recipients, in whom it can be treated by a reduction in the level of immunosuppression. We postulated that the tissue expression of the small RNA transcribed by the EBER-1 gene during latent EBV infection would identify patients at risk for PTLD.

Methods. We studied EBER-1 gene expression in liver specimens obtained from 24 patients 2 days to 22 months before the development of PTLD, using in situ hybridization with an oligonucleotide probe. Control specimens were obtained from 20 recipients of allografts with signs of injury due to organ retrieval, acute graft rejection, or viral hepatitis in whom PTLD had not developed 9 to 71 months after the biopsy.

RESULTS. Of the 24 patients with PTLD, 17 (71 percent) had specimens in which 1 to 40 percent of mononuclear cells were positive for the EBER-1 gene. In addition, 10 of these 17 patients (59 percent) had specimens with histopathological changes suggestive of EBV hepatitis. In every case, EBER-1–positive cells were found within the lymphoproliferative lesions identified at autopsy. Only 2 of the 20 controls (10 percent) had specimens with EBER-1–positive cells (P < 0.001), and such cells were rare.

Conclusions. EBER-1 gene expression in liver tissue precedes the occurrence of clinical and histologic PTLD. The possibility of identifying patients at risk by the method we describe here and preventing the occurrence of PTLD by a timely reduction of immunosuppression needs to be addressed by future prospective studies. (N Engl J Med 1992;327:1710-4.)

METHODS

By reviewing the autopsy and surgical pathology files at the Children’s Hospital of Pittsburgh for the years 1982 through 1989, we identified 24 liver recipients who met the two criteria for entry to our study: PTLD had been diagnosed histopathologically, and at least one liver biopsy specimen obtained before the diagnosis of PTLD was available for evaluation.

Control patients were drawn from the same files as the patients with PTLD. The controls had no documented PTLD during a follow-up period of at least nine months after the performance of the liver biopsy yielding a specimen selected to serve as a control. Pertinent clinical information about the group with PTLD and the control group was obtained from medical records. Histopathological evaluation of the liver specimens selected for study was performed on 4-μm sections of tissue routinely embedded in paraffin and stained with hematoxylin and eosin.

In the in situ hybridization studies of EBV RNA were performed with a 30-base digoxigenin-labeled oligonucleotide complementary to a portion of the EBER-1 gene. The details of the technique have been published elsewhere. The appearance of a brown or blue–brown color in the nucleus was considered a positive reaction. This method has previously detected EBV RNA from an EBV-infected Raji-cell line, but does not detect EBV in the T-cell line Molt, which does not contain EBV. Lymphoid tissue from an EBV-seronegative patient and tissues infected with herpes simplex virus type 1, papillomavirus type 16, and adenovirus showed no cross-reactivity. Tissue from a patient with PTLD who was known to be positive for EBV served as a positive control in each run. Any slide negative for EBV RNA was tested for preservation of RNA with the use of a polydeoxythymidine probe.

The frequency of EBV-infected cells was determined in a semiquantitative fashion by counting the total number of EBER-1–positive cells in relation to the total number of lymphocytes seen in parallel sections prepared from the same biopsy specimen and stained with hematoxylin and eosin. The cells in the hepatic sinusoids and portal tracts were counted. In small specimens, all available cells were counted; in larger specimens, every second or third portal tract was examined.

Immunohistochemical in situ hybridization studies with double labeling were performed on liver blocks obtained at autopsy from four patients with fatal PTLD. Initially, the immunohistochemical reaction was performed according to a previously published method. The antibodies used were directed against LCA (Dako, Carpinteria, Calif.), CD20 (L26, Dako), CD43 (Leu 22, Becton Dickinson, Mountain View, Calif.), Cam 5.2 (Becton Dickinson), and a mixture of anti-keratin antibodies composed of AE, (Hybritech, San Diego, Calif.), Cam 3.2, VCD3 (Triton Biosciences, Alameda, Calif.) and vimentin. Reprinted from the New England Journal of Medicine 327:1710-1714 (December 10, 1992)
Table 1. Clinicopathological Features and EBER-1 Gene Expression in Liver Recipients.

<table>
<thead>
<tr>
<th>FEATURE</th>
<th>CONTROL GROUP (N = 20)</th>
<th>GROUP WITH PTLD (N = 24)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age range (median) — yr</td>
<td>0.8-16 (7.0)</td>
<td>0.5-25.0 (3.7)</td>
</tr>
<tr>
<td>Sex</td>
<td>12/8</td>
<td>10/14</td>
</tr>
<tr>
<td><strong>no. with feature, studied (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBER-1 positivity</td>
<td>2/20 (10)</td>
<td>17/24 (71)*</td>
</tr>
<tr>
<td>EBV seropositivity†</td>
<td>7/15 (47)</td>
<td>10/16 (62)</td>
</tr>
<tr>
<td>Liver histopathology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cellular rejection or ischemic injury§</td>
<td>15/20 (75)</td>
<td>5/24 (21)</td>
</tr>
<tr>
<td>Hepatitis§</td>
<td>5/20 (25)</td>
<td>17/24 (71)</td>
</tr>
</tbody>
</table>

*P<0.001 for comparison of the control group with the group with PTLD, by Fisher’s exact test.
†For details of serologic testing for EBV, see the text.
§Changes reflecting graft rejection and ischemic injury were frequently concurrent.

EBV was attributed to cytomegalovirus or non-A, non-B hepatitis.

The latter group included five patients with concurrent hepatitis and rejection (see the text for detailed histopathological findings).

Calif.), and GN-2 (Enzo Biochemicals, New York). Thereafter, in situ hybridization studies were performed as outlined above.

**RESULTS**

The group with PTLD comprised 10 male and 14 female patients. Their ages at the time of transplantation ranged from 6 months to 25 years (median, 3.7 years). Their diagnoses included a variety of liver disorders, such as biliary atresia, cryptogenic cirrhosis, alpha-antitrypsin deficiency, hereditary cholestasis, and hyperalimentation injury. One patient had received a heart transplant for idiopathic cardiomyopathy. The onset of PTLD occurred a median of 12.5 weeks after transplantation (range, 5 to 640). The anatomical sites involved by PTLD when it was first diagnosed were the liver (seven patients), the tonsils or adenoids (five patients), the gastrointestinal tract (five patients), the trachea (one patient), the bile duct (one patient), the meninges (one patient), and the lymph nodes (one patient); in three patients the disease was disseminated.

The control group consisted of 12 male and 8 female patients 10 months to 16 years old (median, 7 years). The spectrum of primary diseases requiring transplantation in this group was similar to that in the group with PTLD. The biopsy specimens selected as controls were obtained 5 to 1790 days after transplantation (median, 27.5). Histopathological examination generally showed varying degrees of cellular rejection with or without injury due to organ retrieval, as assessed by standard criteria. Two controls had non-A, non-B hepatitis, and three had cytomegalovirus hepatitis (Table 1). These controls had no evidence of PTLD during clinical follow-up lasting 9 to 71 months after liver biopsy (median, 30).

In situ hybridization studies for EBER-1 expression revealed that in 17 of the 24 patients with PTLD (71 percent), one or more liver specimens obtained before the development of PTLD contained from 1 percent to 40 percent EBER-1 mRNA—positive mononuclear cells in the portal tracts and sinusoids (Fig. 1 and 2). In contrast, only 2 of 20 controls (10 percent) had mononuclear cells containing EBER-1 mRNA (P<0.001 by Fisher’s exact test); in both these controls, less than 1 percent of the cells were positive.

Figure 1. Lymphocytic Infiltration of the Hepatic Portal Tracts by Mononuclear Cells Positive for EBER-1 mRNA in a Patient with EBV-Associated Hepatitis.

Panel A (×210) shows scattered EBER-1–positive nuclei in approximately 20 percent of the lymphocytes infiltrating the portal tract. Panel B (hematoxylin and eosin, ×210) shows an infiltrate of activated lymphocytes involving the portal vein and simulating graft rejection.
Generally, the positive cells were small lymphocytes, although some were as large as 20 μm. Hepatocytes, bile-duct epithelial cells, and endothelial cells did not hybridize with the EBER-1 probe. In the group with PTLD, the interval between the detection of EBER-1 mRNA in mononuclear cells and the development of PTLD ranged from 0 to 50 days in 10 patients and from 51 to 100 days in 3 patients; it was more than 100 days in 4 patients. In 1 of these 17 patients, rare EBER-1 mRNA-positive cells were detected 660 days before the onset of PTLD. In 10 of the 17 patients in whom EBV-positive cells were identified, the subsequent PTLD involved the liver, whereas in the other 7 patients it involved other organs. Expression of the EBER-1 gene could be demonstrated in each of 11 specimens of tissue involved by PTLD that were studied by in situ hybridization (Fig. 3). These tissues contained abundant EBER-1-positive mononuclear cells, which accounted for more than 80 percent of the total lymphoid-cell population in some patients. Small round lymphocytes as well as cells with blastic transformation contained EBV mRNA. As in three previously reported cases of PTLD,13 rare hepatocytes also showed staining for EBER-1 mRNA (Fig. 4). Bile-duct epithelial cells and endothelial cells were negative in all patients. Double-labeling studies showed that the majority of the lymphoid cells positive for EBER-1 mRNA had membranes positive for CD20, a finding consistent with B-cell lineage (Fig. 5). However, cells coexpressing CD43 and EBER-1 mRNA, presumably representing T cells, were also present in small numbers.

Serologic data temporally related to the biopsy were obtained for 16 of the 24 patients with PTLD (through the courtesy of Dr. M.C. Breinig, University of Pittsburgh). Six patients were judged either to be seronegative for EBV or to have titers transiently positive for EBV because of multiple perioperative blood transfusions; all were negative for EBER-1 mRNA. The other 10 patients were seropositive and found to be positive.
Rare EBER-1-positive nuclei were found in cells conclusively identified as hepatocytes, by simultaneous immunohistochemical evaluation with the anti-keratin antibody Cam 5.2.

for EBER-1 mRNA as well. Serologic data were available for 15 of the 20 controls. Both EBER-1-positive controls were seropositive for EBV; one was undergoing primary seroconversion at the time of biopsy. Five controls were seropositive for EBV but EBER-1-negative. The eight other controls were seronegative as well as EBER-1-negative.

Histopathological examination of liver specimens from the 17 patients with PTLD whose mononuclear cells were positive for EBER-1 mRNA showed that 15 patients had changes indicating EBV hepatitis, consisting of activated mononuclear infiltrates in the portal tracts associated with lobular disarray and sinusoidal lymphocytes arranged in linear beads and small aggregates. One patient had mononuclear inflammatory infiltrates that spared the portal tracts and resembled lobular hepatitis. Five patients, in addition to the changes of EBV hepatitis, had a mixed lymphocytic, polymorphonuclear, and eosinophilic portal-tract infiltrate associated with bile-duct injury, indicating a mild acute cellular rejection. One patient had a necrotizing granulomatous hepatitis with adenovirus inclusions. When PTLD supervened in the patients with EBV hepatitis, the mononuclear-cell infiltrates expanded and acquired atypical nuclear characteristics.

Liver specimens obtained from 7 of the 24 patients before PTLD developed were negative for EBER-1 mRNA. The histologic correlates of these tissues were mild acute cellular rejection with or without coexisting injury due to organ retrieval (five patients) or injury due to hyperalimentation (one patient); nonspecific changes consisting of mild hepatocellular swelling with scattered polymorphonuclear leukocytes and lymphocytes in the sinusoids were observed in one patient (Table 1).

**DISCUSSION**

The oropharyngeal mucosa, parotid and lacrimal glands, lymph nodes, and circulating lymphocytes are known to be anatomical sites where latent EBV may persist after acute infectious mononucleosis. The present study indicates that lymphocytes of the hepatic portal tract and sinusoids can also harbor EBV, and that an increase in the number of EBER-1-positive cells precedes clinically and histologically evident PTLD. The detection of such EBV-positive cells in the absence of evidence of graft rejection should prompt the physician to consider decreasing the level of immunosuppression, since EBV infections, even when PTLD is advanced, are responsive to immunomodulation. 2

Prospective studies will be necessary to assess the positive predictive value of EBER-1-positive cells in regard to the possible development of PTLD in a particular patient.

The presence of EBV-positive lymphoid cells before the occurrence of lymphoproliferative disease has also been observed in lymph nodes from patients with the acquired immunodeficiency syndrome; this finding is consistent with current notions of a multistep process of carcinogenesis induced by EBV. 18-21 The possible role of EBER-1 mRNA in the evolution of PTLD is unknown, but it has been suggested that EBER-1 genes direct the synthesis of critical viral proteins in vivo. 22

The fact that EBV-positive cells in PTLD lesions

---

![Figure 4. Fatal PTLD Involving Hepatocytes (×630).](image)

**Figure 4.** Fatal PTLD Involving Hepatocytes (×630).

Rare EBER-1-positive nuclei were found in cells conclusively identified as hepatocytes, by simultaneous immunohistochemical evaluation with the anti-keratin antibody Cam 5.2.

---

![Figure 5. EBV-Infected Lymphocytes in the Lesions of PTLD (×420).](image)

**Figure 5.** EBV-Infected Lymphocytes in the Lesions of PTLD (×420).

Immunohistochemical evaluation with anti-CD20 antibody, combined with in situ hybridization, showed that in PTLD the majority of EBV-infected lymphocytes are B cells. Cells positive for CD20 are stained brown, and those positive for EBER-1 mRNA are stained blue-black.
were generally positive for CD20 is consistent with the notion that the EBV receptors required for the virus to enter the cells are normally found on B cells.\textsuperscript{23} The less frequent occurrence of EBER-1 mRNA in CD43-positive cells adds to growing evidence that benign as well as neoplastic T cells can occasionally be infected with EBV.\textsuperscript{24,25}

Several authors have described the histopathological features of clinically presumed EBV hepatitis in patients who were not graft recipients.\textsuperscript{26} Our study documents the presence of EBV-infected cells in the liver tissue of transplant recipients. EBV hepatitis in liver allografts may be overlooked if the pathologist does not pay close attention to lobular disarray and sinusoidal lymphocytosis. The demonstration of the presence of a virus by in situ hybridization is very helpful in reaching a diagnosis when mononuclear infiltrates are subtle, but it is unnecessary when numerous transformed lymphocytes can be clearly seen within the sinusoids, arranged in discrete aggregates and linear chains. However, serologic data should be obtained in the latter case, since non-A, non-B hepatitis can cause similar changes.\textsuperscript{30}

We are indebted to Professor Monto Ho and Dr. Mary C. Breining (Department of Infectious Disease and Microbiology, University of Pittsburgh) for providing the serologic findings about EBV status.

**REFERENCES**


